A significant problem affecting gene therapy approaches aiming at achieving long-term transgene expression is the immune response against the protein product of the therapeutic gene, which can reduce or eliminate the therapeutic effect. The problem is further exacerbated when therapy involves targeting an immunogenic tissue and/or one with a pre-existing inflammatory phenotype, such as dystrophic muscles. In this proof-of-principle study, we co-expressed a model antigen, bacterial β-galactosidase, with an immunosuppressive factor, indoleamine 2,3-dioxygenase 1 (IDO1), in muscles of the mdx mouse model of Duchenne muscular dystrophy. This treatment prevented loss of expression of the transgene concomitant with significantly elevated expression of T-regulatory (Treg) markers in the IDO1-expressing muscles. Moreover, co-expression of IDO1 resulted in reduced serum levels of anti-β-gal antibodies. These data indicate that co-expression of genes encoding immunomodulatory enzymes controlling kynurenine pathways provide a viable strategy for preventing loss of transgenes targeted into dystrophic muscles with pre-existing inflammation.
INTRODUCTION
A common problem in the development of gene therapy for inherited deficits is the risk of immune responses against the re-expressed therapeutic protein. Such protein, due to the total absence of its endogenous expression or because of differences with the endogenous mutant gene product, becomes a neoantigen. The transgene-expressing cells also become the immune response target, which leads to the cessation of the therapeutic effect and often to further tissue damage. 1, 2 The consequences to the recipient can range from transient without significant impairments to severe and life threatening. Many factors affect the immunogenicity of therapeutic proteins. Some of these are protein-related, for example, dose and antigenicity. Others are disease/tissue-related, for example, the underlying immune status and the target tissue promoting immune responses. Skeletal muscle is an immunogenic location 3 and muscle diseases are often associated with chronic sterile inflammation, which exacerbates the highly unfavourable environment.
Duchenne muscular dystrophy (DMD) is an inherited musclewasting disease 4 with inflammation 5 leading to severe disability and death of young men. Currently, no treatment improves the long-term outcome. Unfortunately, there is evidence that immunogenic epitopes resulting from new therapeutic modalities aiming at restoration of dystrophin expression [6] [7] [8] [9] can result in treatment failure in both experimental and clinical trials. 10 Therefore, prevention/suppression of immune responses is prerequisite for successful therapies. Although broad immunosuppression has been shown to prolong transgene expression, 11, 12 it disrupts immune responses against pathogens, which is not without risks in already heavily handicapped patients. In contrast, development of methods to induce tolerance to a therapeutic protein would provide a significant advancement in gene therapy.
Although expression of protein in a naive organism usually causes immunization, it may also lead to the development of the immune tolerance. Mechanisms causing the switch between T-cell response and unresponsiveness include T-cell anergy, clonal deletion of antigen-specific T lymphocytes and regulatory T-cell (Treg) activation. 13 Whether a T cell becomes an effector cell or is tolerized depends on the status of antigen-presenting cells (APCs) that interact with it. [14] [15] [16] [17] [18] This activation status of APCs is, in turn, dependent on the inflammatory signals provided by tissue damage, cytokine content, gene therapy vector and inflammatory signals. The catabolism of the essential amino acid L-tryptophan by indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) enzymes produces kynurenines, which regulate innate and adaptive immune system and maintain tolerance to 'self' antigens. 19 IDO1 has a key role in fetal-maternal tolerance, and animals exposed to antigen neonatally were found unable to mount humoral or cytotoxic responses when re-challenged with DNA constructs encoding such antigens as adults. [20] [21] [22] [23] Importantly, there is evidence that IDO1 induces peripheral tolerance and the retro-control of immune responses. 24 We provide a proof-of-principle that co-triggering the kynurenine mechanism prolongs expression of a model antigenic transgene in adult dystrophic mdx mouse muscles. Importantly, the IDO does not need to be targeted to specific cells.
RESULTS AND DISCUSSION
To minimize the confounding immunizing and immunomodulatory effects of viral vector proteins, we used intramuscular targeting of plasmid vectors expressing bacterial β-galactosidase (lacZ gene) model antigen alone or co-expressed with mouse IDO1.
Engineering, expression and characterization of vectors The choice of the promoter/enhancer elements controlling the transgene can seriously affect its immunogenicity. The ubiquitously active control elements (for example, CMV) trigger immune responses because transgenes become expressed directly in the APCs, which results in increased antigen presentation 25 and rapid recruitment of cytotoxic T cells (CTLs). Tissue-specific promoter/ enhancer control can improve the duration of transgene expression. Nevertheless, for many transgenes, immune responses (albeit humoral, of lower magnitude and delayed in comparison with the CMV-driven construct) are still being triggered because proteins released from cells are processed and presented by APCs, which causes activation of T-helper cells and ultimately the response. Therefore, to maximize the immunogenic effect, we used the CMV promoter. For tolerance induction, we generated two mouse IDO1-expressing plasmids: pcDNA3.CMV.mIDO1 driven by the same ubiquitously active CMV and pcDNA3.CD11c.mIDO1 controlled by the minimal CD11c promoter shown previously to be active primarily in dendritic cells and macrophages. [25] [26] [27] The pcDNA3.CD11c.mIDO1 was made by excision of the CMV promoter using MfeI and Acc65I and ligation of the fragment containing the 760 bp mouse CD11c minimal promoter region. The expression of IDO1 from these constructs was assessed following transfection of SC5 dystrophic myoblasts. 28 HEK-293 cells or RAW264.7 mouse macrophages in vitro and western blotting confirmed IDO1 protein being expressed in transfected HEK293 cells (Figure 1a ). The same approach was used to confirm expression of the pcS2+β-gal plasmid (Figure 1b) .
Co-administration of IDO1 plasmid reduces loss of β-gal expression in skeletal muscles in vivo We targeted β-gal into Tibialis anterior muscles of 4-week-old male mdx mice as, at this stage, the mdx muscle has all the hallmarks of the disease with its highly inflammatory environment. β-gal expression was initially analysed 7, 14 and 21 days following a single intramuscularly plasmid injection. This time-course analysis revealed that β-gal was readily detectable in injected muscles at 7 days. Protein expression was decreased at 14 and undetectable at 21 days (Figure 2a ). Subsequently, this plasmid dose was injected alone (control) or co-injected with one of the IDO1-expressing plasmids and β-gal expression was analysed at 14 days (Figures 2b-d) .
Western blotting analysis of muscle extracts revealed that only 25% of muscles injected with the lacZ plasmid alone had detectable β-gal protein expression 14 days post injection. In contrast, 69% of muscles co-injected with pcDNA3.CMV.mIDO1 plasmids showed detectable β-gal expression while co-injection with pcDNA3.CD11c.mIDO1 plasmid (targeting IDO1 to APCs) resulted in protein being expressed in 42% of muscles ( Figure 2b ). Therefore, IDO1 does not need targeting to APCs. At the equal dose, the qPCR (quantitative PCR) analysis (Figure 2c ) demonstrated that the individual expressions of the lacZ transcript relative to GAPDH endogenous control were higher in the majority of co-injected samples but the averages did not differ significantly due to highly variable expression levels and the relatively low sample number. However, injection of double the amount of β-gal plasmid in the control group resulted in statistically significant reduction rather than increase of this protein expression, thus confirming that higher β-gal expression in co-injected muscles was due to the IDO1 immunosuppression (Figure 2d ). The lacZ expression heterogeneity was confirmed in the muscle sections stained with X-gal: Some of the fibres were strongly labelled while others were expressing very low transgene levels ( Figure 3) . This was in agreement with previous studies using injection of naked lacZ plasmids into skeletal muscles.
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IDO1 expression changes the inflammatory profile in injected muscles Analysis of serial transverse sections of TA muscles showed inflammatory cells to be surrounding and infiltrating both the highly and the weakly expressing fibres (Figure 3 ). There was no significant difference between samples injected with β-gal or co-injected with IDO1 plasmids. The immunohistochemical analysis of markers for the specific inflammatory cell subpopulations infiltrating the tolerized vs non-tolerized muscles was inconclusive (data not shown).
To distinguish the exogenous from the endogenous IDO1 expression, we used RT-PCR (PCR with reverse transcription) with primers detecting the plasmid-driven transcript only (Figure 4a) . Having confirmed the exogenous IDO1 expression, qPCR was used to establish the relative levels of IDO1 mRNA and that confirmed a statistically significant increase in the co-injected muscles (Figure 4b) .
The qPCR analysis of several key marker genes for different T-cell subsets showed statistically significant increase in the expression of Cd4, Cd8 and forkhead box P3 (Foxp3) genes in muscles co-injected with IDO1 plasmids ( Figure 5 ). This pattern is interesting as increased expressions of lymphocyte markers were concomitant with higher levels of Foxp3. This transcription factor regulates the development and function of T-regulatory (T-reg) cells 30 and therefore overexpression of IDO1 appears to prolong antigen expression via the induction of T-regs.
The levels of interleukin 10 (Il10) and Il12a expression did not show statistically significant differences in these samples ( Figure 5 ). Previous studies demonstrated regulatory interactions between IDO1, IL-10 and IL-12 in antigen presenting cells 31, 32 and IDO1 suppresses the IL-10, as kynurenic acid reduces IL-10 production. 33 Interestingly, the decrease in expression of IL-10, which is an anti-inflammatory cytokine 34, 35 and one of the mediators of T-reg functions, did not reach statistical significance in IDO-1-expressing muscles. Similarly IL-12, which is involved in the development of Th1 CD4 + T cells, which leads to cytotoxic T-lymphocyte activation 36 and also activate natural killer cells 37 was not significantly reduced, although its levels were consistently lower in IDO1-injected muscles. Therefore, the IL-10/IL-12 regulatory interplay may still have a role in the local microenvironment but changes may not be detected when analysed globally in an otherwise inflammatory environment of the dystrophic muscle. Finally, the ELISA performed to quantify the serum anti-β-gal antibody levels showed significantly lower response in animals co-administered with the IDO1 plasmid ( Figure 6 ). This is consistent with the studies in haemophilic mouse models, which revealed that kynurenins prevented generation of anti-FVIII antibodies and suppressed FVIII-specific B cells by a mechanism involving the IDO1-dependent induction of T-regs. 38 Interestingly, a recent study demonstrated a novel role for IDO1, intrinsic to B cells, where it acts as a regulator of humoral immunity. 39 Together, these and our findings indicate that IDO1 strategies for preventing immunization in gene therapy approaches should be explored while further studies are needed to help our understanding of the exact mechanism(s) involved.
In summary, this proof-of-principle study was performed to demonstrate that local expression of even strong non-self antigens in tissues with pre-existing inflammation can be prolonged using enzymes modulating kynurenine pathways. These data point towards a viable strategy for preventing transgene loss in various gene therapy settings. Recently, this approach was used to induce tolerance to transplanted organs, thus reducing need for immunosuppressive treatments. 40 
MATERIALS AND METHODS
The mdx C57Bl/10ScSn-Dmdmdx/J 4-week-old male mice were used in accordance with the institutional Ethical Review Board and the Home Office (70/7549) approvals.
The lacZ (pcS2+Cβ-gal) and the primary pcDNA3.IDO1 plasmids were obtained via collaboration (see 'Acknowledgements' section).
The following antibodies were used: anti-βgal (ThermoFisher Scientific, Paisley, UK; A11132), anti-IDO clone 10.1 (Merck Millipore, Watford, UK; 05-840), anti-actin (A2066) and anti-GAPDH (G9545, both Sigma, Gillingham, UK).
RT-PCR and qPCR analyses Total RNA was extracted using RNeasy kit (Qiagen, Manchester, UK) as per the manufacturer's instructions. One microgram of RNA was used for cDNA synthesis and 100 ng of cDNA in RT-PCR. Identification of the exogenous (plasmid-driven)IDO1 was performed using primers: Fv 5′-GAGGCTGGCAAAGATCTCCTGC-3′ and Rv 5′-GCTCGAGCGGCCGCCTA-3′ in 35 cycles: 94°C; 60°C, 72°C for 1 min each, followed by a final 9 min elongation step at 72°C.
Quantitative PCR analyses of Cd4, Cd8, Foxp3, Il10 and Il12 transcripts were performed using 25-50 ng of cDNA with Taqman probes (Applied Biosystems, Paisley, UK) and ViiA 7 Real-Time PCR System (Life Technology, Paisley, UK). All individual muscles were analysed in triplicate and all the samples run on the same plate to avoid inter-run variation. Gapdh was previously determined to be the most stably expressed gene in dystrophic muscles 41 and thus used as reference to establish individual gene expression values (2 -ΔΔCT ).
Construction of cd11c.IDO1 expression vector
The minimal functional region of the 5.3 kb CD11c promoter 25, 26 was amplified from the pBluescript.CD11c.Beta Globin Ova I plasmid (gift from Dr Thomas Brocker) using adapter primers Fv 5′-TCAACGCGTCAATTGAGTATTCTCTTGACCTTGGCTGCC-3′ and Rv 5′-TGAGGTACCGACTGGAGAACAGAAGCAGGC-3′ with MfeI and Acc65I restriction sites for 35 cycles ( 94°C, 67°C and 72°C for 1 min each) followed by the final elongation step at 72°C. The 760 bp amplicon was isolated from an agarose gel, purified and cloned into pcDNA3.CMV.mIDO1 digested with MfeI and Acc65I that removed the CMV promoter cassette, resulting in the pcDNA3. CD11c.mIDO1 plasmid. Positive clones were verified by DNA sequencing. High-purity, endotoxin-free plasmids were made using Endofree Mega Kit (Qiagen).
In vitro cell transfection HEK-293 and SC5 myoblast cells were authenticated (PowerPlex 16 HS, Promega, Southampton, UK and MycoAlert PLUS Mycoplasma Detection Kit, Lonza, Slough, UK) and cultured as previously described. 28 Twenty-four hours before transfection 250 000 cells were plated in 35 mm dishes. Two microgram of endotoxin-free plasmid was diluted in Knockout-DMEM (Thermofisher, Paisley, UK) and complexed with Lipofectamine, GeneCellin (BiocellChallenge, Signes, France), FuGene HD (Promega) and K2 (Biontex, Munchen, Germany) at 37°C for 15 min. The transfection reagents were dispersed and cells grown for 24 h, transfection mixtures replaced with the complete medium: Knockout-DMEM with serum (Thermofisher) and total proteins extracted after 72 h.
Analysis of transgene expression in vivo
Plasmids were diluted in 0.9% saline. For the co-injection experiments, the lacZ plasmid was mixed 1:1 (molar ratio) with either pcDNA3.CMV.mIDO1 or pcDNA3.CD11c.mIDO1. Anaesthetized mdx mice were allocated randomly to the experimental and Figure 5 . Inflammatory gene expression changes in IDO1 co-injected muscles. Individual values plot of the relative expression levels (2 − ΔΔCT ) demonstrate significant differences in expression levels of Cd4 (n = 4, P = 0.018, sidebar = 0-6), Cd8 (n = 4, P = 0.025, sidebar = 0-5) and Foxp3 (n = 4, P = 0.034, sidebar = 0-8) in co-injected muscles 14 days post-injection while Il-10 (n = 6, P = 0.124, sidebar = 0.0-2.0) and Il-12 (n = 4, P = 0.132, sidebar = 0.0-3.5) levels were not altered significantly.
control groups and injected aseptically into both Tibialis anterior muscles with 25 μl per muscle (1 μg μl − 1 ) using the 27G1/2 needle fitted with a plastic collar to maintain depth of injection constant. 42 At specific times post injection, the mice were killed by CO 2 inhalation and muscles flash-frozen in liquid nitrogen. The blood was collected and serum prepared using a standard method. 41 Protein extraction Frozen TA muscles were crushed in liquid nitrogen and tissue powders re-suspended in 200 μl ice-cold extraction buffer (1 × cOmplete Lysis M (Roche, Welwyn Garden City, UK), 1 × cOmplete ULTRA Mini EDTA-free protease inhibitor cocktail tablet, 1 × x PhosSTOP phosphatase inhibitor cocktail tablets (Roche)). The samples incubated on ice for 30 min with occasional vortexing were homogenized further by passing through 27½G needle (3 × ), centrifuged at 16 000 g for 5 min and protein concentrations in supernatants measured using the Bicinchoninic acid kit (Sigma).
Western blotting Protein (40-60 μg) was resolved on SDS-PAGE gel and blotted onto Hybond-P membranes (GE Healthcare, Amersham, UK). The blots were blocked in 5% w/v non-fat milk in TBST for 1 h before probing with a primary antibody (overnight at 4°C), washed with TBST (10 min, 3 × ) and incubated with the appropriate HRPconjugated secondary antibody for 1 h at room temperature. Specific protein bands were visualized using Luminata Forte or Crescendo chemiluminescent substrates (Merck Millipore), images obtained using G-Box (Syngene, Cambridge, UK). Densitometric analyses of protein bands were made using exposure times within the linear range and the integrated density measurement function of Fiji software. 43 Histological muscle analyses Five to 10 μm thick muscle cryosections were fixed in 4% w/v paraformaldehyde solution, washed in PBS (phosphate-buffered saline) and stained for 3 days at 37°C in PBS with 500 μg ml − 1 X-gal (Promega), 5 mM potassium ferricyanide (III), 5 mM potassium hexacyano ferrate (II), 2 mM magnesium chloride (all Sigma) and 0.02% Nonidet P40 (Calbiochem, Watford, UK). The sections were washed with TBST, counterstained with haematoxylin and eosin and images captured using Axiophot (Zeiss, Jena, Germany) microscope. ELISA Serum antibody levels were measured as described previously. 1, 44 Ninety-six-well Maxisorp plates (Nunc, Fisher, Loughborough, UK) were coated with 100 μl per well βgal (Roche) at 10 μg ml − 1 in bicarbonate buffer (pH 9.6) overnight at 4°C, washed with TBST and incubated at room temperature for 1 h with 200 μl per well of blocking buffer (2% Tween 20 in PBS without Ca 2+ /Mg 2+ ). Hundred microlitres per well of serum (1:100 to 1:5000 in PBS, 2% Tween 20; analysed in triplicate) or, for standard curve, mouse anti-βgal antibody (1:200 to 1:40 000; Sigma) were incubated at room temperature for 2 h. After washing, the samples were incubated with goat anti-mouse HRP antibody (1:5000; Sigma) for 2 h at room temperature in the dark, washed and incubated with TMB substrate (BD Biosciences, Oxford, UK) at 37°C for~10 min. The reaction was stopped with 2 M H 2 SO 4 and read at 450/550 nm in a plate reader (Dynex MRX TC II) against the standard curve.
Statistical analysis of the data All the experiments were repeated at least three times. The data are presented as means ± s.e.m. All the results were analysed using Student's t-test or analysis of variance with Tukey's multiplecomparison post hoc test and P o 0.05 was considered as statistically significant. Figure 6 . Co-expression of IDO1 reduces antibody response against β-gal. The levels of anti-β-gal antibodies 14 days post injection were significantly lower in sera from mice co-expressing the CMV-driven IDO1 plasmid (P = 0.023, analysis of variance with Tukey's test). β-gal, n = 7; β-gal+CD11c.mIDO1, n = 5; β-gal+CMV.mIDO1, n = 6. NS, not significant.
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